Cellectar Biosciences Statistics
Total Valuation
CLRB has a market cap or net worth of $16.15 million. The enterprise value is $4.03 million.
Important Dates
The next estimated earnings date is Thursday, March 12, 2026, before market open.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLRB has 4.24 million shares outstanding. The number of shares has increased by 93.70% in one year.
| Current Share Class | 4.24M |
| Shares Outstanding | 4.24M |
| Shares Change (YoY) | +93.70% |
| Shares Change (QoQ) | +96.55% |
| Owned by Insiders (%) | 4.27% |
| Owned by Institutions (%) | 8.59% |
| Float | 4.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.63 |
| P/TBV Ratio | 2.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.77 |
| Quick Ratio | 2.56 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -145.42% and return on invested capital (ROIC) is -139.71%.
| Return on Equity (ROE) | -145.42% |
| Return on Assets (ROA) | -72.31% |
| Return on Invested Capital (ROIC) | -139.71% |
| Return on Capital Employed (ROCE) | -309.14% |
| Weighted Average Cost of Capital (WACC) | 5.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLRB has paid $66,000 in taxes.
| Income Tax | 66,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.89% in the last 52 weeks. The beta is 0.32, so CLRB's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -48.89% |
| 50-Day Moving Average | 3.30 |
| 200-Day Moving Average | 5.55 |
| Relative Strength Index (RSI) | 58.38 |
| Average Volume (20 Days) | 131,630 |
Short Selling Information
The latest short interest is 83,230, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 83,230 |
| Short Previous Month | 106,028 |
| Short % of Shares Out | 1.96% |
| Short % of Float | 2.05% |
| Short Ratio (days to cover) | 1.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -30.03M |
| Pretax Income | -18.79M |
| Net Income | -18.85M |
| EBITDA | -29.80M |
| EBIT | -30.03M |
| Earnings Per Share (EPS) | -$9.76 |
Full Income StatementBalance Sheet
The company has $12.55 million in cash and $431,929 in debt, with a net cash position of $12.12 million or $2.86 per share.
| Cash & Cash Equivalents | 12.55M |
| Total Debt | 431,929 |
| Net Cash | 12.12M |
| Net Cash Per Share | $2.86 |
| Equity (Book Value) | 9.38M |
| Book Value Per Share | 2.34 |
| Working Capital | 8.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.69 million and capital expenditures -$61,286, giving a free cash flow of -$29.75 million.
| Operating Cash Flow | -29.69M |
| Capital Expenditures | -61,286 |
| Free Cash Flow | -29.75M |
| FCF Per Share | -$7.02 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
